about
TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signalingSmad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organizationDecentralized data sharing of tissue microarrays for investigative research in oncologyOvarian cancer detection by logical analysis of proteomic data.A prototype for unsupervised analysis of tissue microarrays for cancer research and diagnostics.Unsupervised imaging, registration and archiving of tissue microarrays.TGF-beta and cancer.Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice.Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition.Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element.Resistance of human squamous carcinoma cells to transforming growth factor beta 1 is a recessive traitTGFbeta superfamily signaling: notes from the desertTransforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging.Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta ) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent.Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbetaMechanisms involved in the induction of malignant cell differentiation.Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer.A novel vitamin D derivative activates bone morphogenetic protein signaling in MCF10 breast epithelial cells.Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer.Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2.Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer.Restoration of differentiation and suppression of tumorigenicity in somatic cell hybrids of human squamous carcinoma cells and keratinocytes.Reversible effects of retinoic acid on glycosaminoglycan synthesis during differentiation of HL-60 leukemia cells.Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.A young woman with recurrence of breast cancer.Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells.Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis.Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis.Modulation of the terminal differentiation of human squamous carcinoma cells in vitro by all-trans-retinoic acid.Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms.High frequency of resistance of human squamous carcinoma cells to the anti-proliferative action of transforming growth factor beta.Cryopreservation of human monocytesInhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor- Type I Receptor Kinase In vivoFrequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells
P50
Q24569549-63A90CA0-D4BE-40E8-8CB0-77561A99580FQ28567374-6D33B050-D6A5-4207-980D-D8C5C3DEE41DQ28762550-A55BF608-802F-40BB-B836-E163D93CD965Q30909733-C2782080-4B7D-4115-B7CB-441C1303D7EAQ31082534-178E1F10-1301-4087-B737-EF4EAFC53038Q31120208-507F48F1-2DA4-4E4E-97C1-53D4B43F671EQ33804136-536F3683-E13F-4E67-A516-DA972988A213Q33867525-468E6C63-8E5C-473A-8843-29CAE6642084Q33933880-A0E828E8-42EA-4498-AD46-5EB059B540DEQ35025142-6FEB4357-78CB-4A1A-B03E-85845BAAA2B2Q35117549-13D2B5AB-6FAE-4761-8ABD-C5E195D62597Q36003640-612EA884-1A86-4C6C-8F3A-946DDC1C9EDBQ36404409-29B04B77-F087-4540-A1C7-8419244CA6EDQ36955771-063A446F-C9DD-424F-BA2D-8F4D7201FCE5Q38010271-CEEF68B0-8AFD-4EA6-8BE7-B714796DCAD4Q38358348-9D9DADC7-30F0-46BF-AB50-CB66C80D699FQ39331254-B0EAC735-9DF6-48D4-AB95-F279808C00EFQ39756628-AF3994C3-7A50-4237-B1A6-4DDB1773B6B9Q40273438-FF61BEEA-8E1E-4FAB-A7C6-439EEA5F552FQ40305536-E40C837A-D2BB-4813-AE61-17223E0B65FAQ40492547-7F43FAC8-0922-4977-BA11-032F327235C2Q40585969-718A9A38-0CC3-436A-84DB-097637E1112FQ40961407-0DD78978-8417-4100-99ED-B12AD5417C22Q41425038-B9ED6C03-6CC6-4422-8FDD-277FFF9BD691Q42224596-36E69232-4BE7-4772-918C-3836EF411A7CQ42435214-ECE059D4-B463-43A7-82EB-B4C595775267Q43923186-D6F65CFA-7766-4964-AD5F-7AC2FF8AA394Q44435206-1430E297-12E7-48B2-AC21-8FD33354F1A7Q45003991-704BF1FF-8EFB-4E6E-8CAE-67EB29F9FD8AQ45345219-96F204B9-8187-4676-8454-CA87CA1E251AQ45345223-FFC0F078-8A17-45E4-9BA6-A63684AAA9E9Q52546101-85C231FA-F5A7-4F41-86C1-B0C48B63D293Q52551767-DE207F35-7BA7-4044-A247-99A579030756Q52552644-16CC3650-266A-4505-A7B7-3F56F4CDDAC2Q53436580-A6634AEF-274D-4BDB-8183-4BB38293AC88Q53451274-DF843086-9DCD-4021-9445-C1D80CFFAA18Q53510902-3A2BBACB-3524-4364-B526-FA388052FCE5Q57119356-8752301D-7E78-46D2-8061-B4B8C44A1307Q59383502-5F6F464D-950F-47E4-98C2-BCE6787117B4Q59491734-9AD7B95D-6DD8-4BC1-9748-DB1139E4F1C9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael Reiss
@ast
Michael Reiss
@en
Michael Reiss
@es
Michael Reiss
@nl
type
label
Michael Reiss
@ast
Michael Reiss
@en
Michael Reiss
@es
Michael Reiss
@nl
prefLabel
Michael Reiss
@ast
Michael Reiss
@en
Michael Reiss
@es
Michael Reiss
@nl
P106
P108
P31
P496
0000-0001-8543-8092